Cite
HARVARD Citation
Khwaja, J. et al. (2022). Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis. EJHaem. 3 (4), pp. 1330-1334. [Online].